- Home
- NBXG vs ATAI Comparison
NBXG vs ATAI Comparison
Compare NBXG & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBXG
- ATAI
- Stock Information
- Founded
- NBXG 2021
- ATAI 2018
- Country
- NBXG United States
- ATAI Netherlands
- Employees
- NBXG N/A
- ATAI N/A
- Industry
- NBXG Trusts Except Educational Religious and Charitable
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- NBXG Finance
- ATAI Health Care
- Exchange
- NBXG Nasdaq
- ATAI Nasdaq
- Market Cap
- NBXG 1.1B
- ATAI 1.1B
- IPO Year
- NBXG N/A
- ATAI 2021
- Fundamental
- Price
- NBXG $15.22
- ATAI $5.77
- Analyst Decision
- NBXG
- ATAI Strong Buy
- Analyst Count
- NBXG 0
- ATAI 5
- Target Price
- NBXG N/A
- ATAI $14.00
- AVG Volume (30 Days)
- NBXG 243.7K
- ATAI 7.1M
- Earning Date
- NBXG 01-01-0001
- ATAI 11-14-2025
- Dividend Yield
- NBXG 10.25%
- ATAI N/A
- EPS Growth
- NBXG N/A
- ATAI N/A
- EPS
- NBXG N/A
- ATAI N/A
- Revenue
- NBXG N/A
- ATAI $2,309,000.00
- Revenue This Year
- NBXG N/A
- ATAI $736.04
- Revenue Next Year
- NBXG N/A
- ATAI N/A
- P/E Ratio
- NBXG N/A
- ATAI N/A
- Revenue Growth
- NBXG N/A
- ATAI 510.85
- 52 Week Low
- NBXG $9.31
- ATAI $1.04
- 52 Week High
- NBXG $12.23
- ATAI $6.75
- Technical
- Relative Strength Index (RSI)
- NBXG 54.88
- ATAI 52.96
- Support Level
- NBXG $15.11
- ATAI $5.73
- Resistance Level
- NBXG $15.53
- ATAI $6.23
- Average True Range (ATR)
- NBXG 0.23
- ATAI 0.47
- MACD
- NBXG 0.02
- ATAI -0.05
- Stochastic Oscillator
- NBXG 67.37
- ATAI 42.34
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.